Raymond James Financial Inc. Invests $3.63 Million in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Raymond James Financial Inc. acquired a new stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 727,118 shares of the biotechnology company’s stock, valued at approximately $3,628,000. Raymond James Financial Inc. owned about 1.22% of Aldeyra Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in ALDX. State Street Corp raised its stake in shares of Aldeyra Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock valued at $5,249,000 after acquiring an additional 16,188 shares during the period. Jacobs Levy Equity Management Inc. increased its holdings in Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after purchasing an additional 295,864 shares during the last quarter. Woodstock Corp raised its position in Aldeyra Therapeutics by 7.8% in the fourth quarter. Woodstock Corp now owns 194,919 shares of the biotechnology company’s stock valued at $973,000 after purchasing an additional 14,113 shares during the period. Barclays PLC lifted its stake in Aldeyra Therapeutics by 280.1% during the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock worth $353,000 after purchasing an additional 48,313 shares in the last quarter. Finally, AlphaCentric Advisors LLC purchased a new position in shares of Aldeyra Therapeutics during the fourth quarter worth $234,000. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Monday, March 3rd.

Aldeyra Therapeutics Stock Down 0.6 %

Shares of ALDX opened at $6.26 on Friday. Aldeyra Therapeutics, Inc has a fifty-two week low of $3.10 and a fifty-two week high of $7.20. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. The firm’s 50 day moving average price is $6.06 and its 200 day moving average price is $5.52.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.30). As a group, analysts predict that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.